Elliot, great piece! Would love to hear to your thoughts on the clinical trial bottleneck and potential solutions/companies that are tackling this massive problem. I really think solving the clinical trial problem will allow for a complete realignment of the pharmaceutical/biotech industry around transformational therapies, preventative medicine, and a focus on the health afflictions of the many not just the rare diseases of the few (still important).
During the last biotech boom in the 2000s I read where a consortium (or was it just Germany?) we're essentially building a human body with software that could simulate how novel drugs would interact and thereby sidestep some of the "clinical bottleneck". I haven't really heard much about it since--Im sure it was way to complex to tackle 20 years ago, probably even today, but is anyone working along these lines?
Elliot, great piece! Would love to hear to your thoughts on the clinical trial bottleneck and potential solutions/companies that are tackling this massive problem. I really think solving the clinical trial problem will allow for a complete realignment of the pharmaceutical/biotech industry around transformational therapies, preventative medicine, and a focus on the health afflictions of the many not just the rare diseases of the few (still important).
During the last biotech boom in the 2000s I read where a consortium (or was it just Germany?) we're essentially building a human body with software that could simulate how novel drugs would interact and thereby sidestep some of the "clinical bottleneck". I haven't really heard much about it since--Im sure it was way to complex to tackle 20 years ago, probably even today, but is anyone working along these lines?